RT Journal Article SR Electronic T1 Extremely potent monoclonal antibodies neutralize Omicron and other SARS-CoV-2 variants JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.01.12.22269023 DO 10.1101/2022.01.12.22269023 A1 Zhaochun Chen A1 Peng Zhang A1 Yumiko Matsuoka A1 Yaroslav Tsybovsky A1 Kamille West A1 Celia Santos A1 Lisa F. Boyd A1 Hanh Nguyen A1 Anna Pomerenke A1 Tyler Stephens A1 Adam S. Olia A1 Valeria De Giorgi A1 Michael R. Holbrook A1 Robin Gross A1 Elena Postnikova A1 Nicole L. Garza A1 Reed F. Johnson A1 David H. Margulies A1 Peter D. Kwong A1 Harvey J. Alter A1 Ursula J. Buchholz A1 Paolo Lusso A1 Patrizia Farci YR 2022 UL http://medrxiv.org/content/early/2022/01/13/2022.01.12.22269023.abstract AB The ongoing coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has triggered a devastating global health, social and economic crisis. The RNA nature and broad circulation of this virus facilitate the accumulation of mutations, leading to the continuous emergence of variants of concern with increased transmissibility or pathogenicity1. This poses a major challenge to the effectiveness of current vaccines and therapeutic antibodies1, 2. Thus, there is an urgent need for effective therapeutic and preventive measures with a broad spectrum of action, especially against variants with an unparalleled number of mutations such as the recently emerged Omicron variant, which is rapidly spreading across the globe3. Here, we used combinatorial antibody phage-display libraries from convalescent COVID-19 patients to generate monoclonal antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein with ultrapotent neutralizing activity. One such antibody, NE12, neutralizes an early isolate, the WA-1 strain, as well as the Alpha and Delta variants with half-maximal inhibitory concentrations at picomolar level. A second antibody, NA8, has an unusual breadth of neutralization, with picomolar activity against both the Beta and Omicron variants. The prophylactic and therapeutic efficacy of NE12 and NA8 was confirmed in preclinical studies in the golden Syrian hamster model. Analysis by cryo-EM illustrated the structural basis for the neutralization properties of NE12 and NA8. Potent and broadly neutralizing antibodies against conserved regions of the SARS-CoV-2 spike protein may play a key role against future variants of concern that evade immune control.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), and by the Intramural Research Program of the VRC, NIAID, NIH. This work was also supported by Federal funds from the NIAID, NIH, under Contract No. HHSN272201800013C, by Federal funds from the Frederick National Laboratory for Cancer Research (FNLCR), NIH, under Contract HHSN261200800001 (YT, TS).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of the National Institutes of Health gave ethical approval for this work (ClinicalTrials.gov Identifier: NCT04360278)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data presented in this study are available within the article or from the corresponding authors upon request. Source data are provided with this paper. The antibody sequences reported in this paper have been deposited in the GenBank database (accession nos. OM179962-OM179997). The ensemble cryo-EM maps of the NE12/spike trimer and NA8/spike trimer complexes were deposited to the Electron Microscopy Data Bank (EMDB) https://www.ncbi.nlm.nih.gov/genbank/